Sun, Jul 13, 2014, 7:19 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

  • kolemup kolemup Jan 7, 2014 4:48 PM Flag

    The key for Zerenex Rejection spelled bellow in official wording...

    Summary / Conclusions
    • Drug development in Japan need not be complicated or
    – Regulations are different, but regulators have flexibility
    – High degree of collaborati
    on between agency/ministry,
    physicians, patients and industry is feasible
    – Agents with strong science or clinical need receive attention
    • Because of differences between Japan versus US/EU,
    good understanding of the Japanese regulations can
    lead to commercialization advantages and opportunities
    – Drugs available elsewher
    e but not approved in Japan
    • Key: Close communication with both the PMDA and the
    – For foreign pharmaceutical/bio
    tech companies, a strong in-
    house Japanese regulatory affairs group or close working
    relationship with external consultants familiar with Japanese
    regulations is a must

    SortNewest  |  Oldest  |  Most Replied Expand all replies
14.84-0.35(-2.30%)Jul 11 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Potbelly Corporation
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
Yamana Gold, Inc.
NYSEFri, Jul 11, 2014 4:00 PM EDT